INPLASY2022120023
Real-world effectiveness and safety of ramucirumab as a second-line treatment for patients with unresectable advanced or metastatic gastric or gastroesophageal junction adenocarcinoma in Eastern Asia: a systematic literature review
![](https://i0.wp.com/inplasy.com/wp-content/uploads/2022/12/INPLASY-Protocol-4224-1.png?fit=849%2C1200&ssl=1)
![](https://i0.wp.com/inplasy.com/wp-content/uploads/2022/12/INPLASY-Protocol-4224-2.png?fit=849%2C1200&ssl=1)
![](https://i0.wp.com/inplasy.com/wp-content/uploads/2022/12/INPLASY-Protocol-4224-3.png?fit=849%2C1200&ssl=1)
![](https://i0.wp.com/inplasy.com/wp-content/uploads/2022/12/INPLASY-Protocol-4224-4.png?fit=849%2C1200&ssl=1)
![](https://i0.wp.com/inplasy.com/wp-content/uploads/2022/12/INPLASY-Protocol-4224-5.png?fit=849%2C1200&ssl=1)